NCT01388088已完成4 期
Effect of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables in Patients With Essential Hypertension in a Doublle-blinded Randomised Placebo-controlled, Cross-over Study.
Erling Bjerregaard Pedersen1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2010年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Blood pressure
研究概览
简要总结
The investigators wish to investigate the potential effects of potassium. In this study we will examine patients with hypertension and increase their potassium-levels using Amiloride and Spironolactone.
The investigators will examine the changes in the cardiovascular system using a Sphygmocor-scanner.
详细描述
Purpose of the study is to examine the effect of amilorid and spironolacton on
- Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK),
- Pulsewavevelocity, augmentation index and centralt bloodpressure,
- Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and
- Ambulatory blood pressure
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 45 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hypertension
- •Age 45-70
- •BMI: 18,5-30
排除标准
- •Other diseases
- •Drug or alcohol abuse
- •Abnormal findings in the screening procedure
研究组 & 干预措施
Amiloride
Active Comparator
Increases the level of potassium
干预措施: Amiloride (Drug)
Spironolactone
Active Comparator
Increases the level of potassium
干预措施: Spironolactone (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Blood pressure
时间窗: 2 years
24 hours blood pressure measurements
次要结局
- Pulse wave velocity(2 years)
研究者
Erling Bjerregaard Pedersen
Proffesor
Regional Hospital Holstebro
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular VariablesEssential HypertensionNCT01195805Regional Hospital Holstebro25
已完成
1 期
The Effect of Amiloride and Spironolactone in Healthy PersonsHigh Blood PressureNCT00857909Regional Hospital Holstebro30
进行中（未招募）
1 期
The effect of Amiloride and Spironolacton on renophysiological and cardiovascular parametres in patients with hypertension - HASSMedDRA version: 12.1Level: LLTClassification code 10004254Term: Benign essential hypertensionHypertensionEUCTR2010-020599-47-DKDepartments of Medical Research and Medicine25
进行中（未招募）
不适用
The effect of Amiloride and Spironolacton on renophysiological and cardiovascular parametres in healthy patientsHypertensionEUCTR2008-003336-38-DKDepartment of Medical Research25
Unknown
不适用
Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney DiseaseDiabetic NephropathiesHypertensionNCT01918488University of Southern Denmark80